IIQ

INOVIQ LTD FPO [IIQ]
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
Healthcare · ASX Small Cap
$0.2000 -4.8%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when IIQ triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track IIQ — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Took a hit — down 11.1% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.43, underperforming its peers
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Strong cash runway (11 quarters)
  • 4C filed 2026-07-12
  • Moderate P/S ratio (13.4x)
  • Strong revenue growth (+35%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (3% of range)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Positive long-term momentum — up 27% over the past year
  • Revenue growing at +35% — the top line is moving in the right direction
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-6.24%/day)
Ask Scout AI about IIQ
"What's driving IIQ today?" "How does IIQ compare to peers?" "Key risks for IIQ?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Change of Director's Interest Notice
NONE EXO-OC Study Outcome Investor Webinar Presentation
NONE Investor Briefing on EXO-OC Test and study outcome
LOW Quarterly Activities Report and Appendix 4C - June 2026

Recent ASX Announcements

2026-07-15 Change of Director's Interest Notice
2026-07-13 EXO-OC Study Outcome Investor Webinar Presentation PRICE SENSITIVE
2026-07-12 Quarterly Activities Report and Appendix 4C - June 2026 PRICE SENSITIVE
2026-07-07 Investor Briefing on EXO-OC Test and study outcome
2026-06-30 EXO-OC algorithm and clinical study update PRICE SENSITIVE

Key Metrics

$28.2M
Market Cap
783K
Avg Volume
0.8x
Vol Ratio
$0.19 — $0.56
52-Week Range
N/A
Short Interest
11 qtrs
Cash Runway
-34.7%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 82%
LLeader vs LaggardlaggardRS: -11
IInstitutional SponsorshipweakInst: 9%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%NTI +12.5%PIQ -11.4%OSL -10.3%
Compare:IIQ vs ECSIIQ vs VHLIIQ vs NTI
Scout Pro — Deeper Analysis for IIQ
Try Pro free for 30 days
Share this analysis

Track IIQ and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required